Patients on Wegovy maintain weight loss for 4 years, finds study by Novo Nordisk

Are you struggling to lose weight? Well, Novo Nordisk may have the solution you’ve been looking for with their obesity drug Wegovy. A new analysis published from the longest clinical trial to date on the treatment has shown that patients maintained an average of 10% weight loss for up to four years. But that’s not all – Wegovy also reduced the risk of heart disease, regardless of a patient’s weight, according to a second analysis on the same trial.

These findings were presented at the European Congress on Obesity in Venice, Italy, showcasing the long-term effects of Wegovy and its broad health benefits. This could potentially lead to increased insurance coverage for the costly but effective drug.

Related:  Experts maintain that Series I bonds remain a favorable investment, despite declining rates

Wegovy belongs to a class of medications called GLP-1s, which have become increasingly popular in the past year due to their ability to mimic a hormone produced in the gut to suppress appetite. However, both Novo Nordisk and Eli Lilly, another company with a weight loss drug, have struggled to keep up with the high demand for these treatments.

The SELECT trial, which included over 17,000 patients from 40 countries, tested Wegovy for its cardiovascular benefits. Participants experienced significant weight loss, and even after stopping the drug, they were able to maintain their weight loss for up to four years. Additionally, patients reaped the heart benefits of Wegovy regardless of their starting weight or how much weight they lost.

Related:  Q1 2024 Earnings Report Released by Eli Lilly & Co. (LLY)

So, if you’re looking for a weight loss solution that not only helps you shed pounds but also improves your heart health, Wegovy might be the answer. Stay tuned for more updates on this groundbreaking treatment on Extreme Investor Network.

Source link